Viewing Study NCT02961218


Ignite Creation Date: 2025-12-25 @ 4:53 AM
Ignite Modification Date: 2026-02-22 @ 7:49 PM
Study NCT ID: NCT02961218
Status: COMPLETED
Last Update Posted: 2021-10-11
First Post: 2016-10-20
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia
Sponsor: Novartis Pharmaceuticals
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Sickle Cell Anemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sickle cell disease View
None hemoglobinopathy View
None pediatric View